Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |  Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 521Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
  Feedback 
  Subscribe 
 Back To Article

  Reader Comments

Year : 2018 | Volume:  9 | Issue Number:  4

LETTER TO EDITOR

From “Glivec®” to “Prevnar 13®”: How strong is the Indian drug patenting system?

Raj Gerard Marshall

Add Your Comments
 
No one has added comments on this article. Click here to add your remarks


 

 

 
Sitemap | What's New Feedback | Copyright and Disclaimer | Privacy Notice
© Perspectives in Clinical Research | Published by Wolters Kluwer - Medknow
Online since 20th October, 2010